Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Warts - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2017, provides an overview of the Warts (Infectious Disease) pipeline landscape. Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 16, 1, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively. Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Warts - Overview 6 Warts - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Pipeline by Universities/Institutes 11 Products under Development by Companies 12 Products under Development by Universities/Institutes 14 Warts - Therapeutics Assessment 15 Assessment by Target 15 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Warts - Companies Involved in Therapeutics Development 23 Aclaris Therapeutics Inc 23 Agilvax Inc 23 Aviragen Therapeutics Inc 24 BioMAS Ltd 24 Cutanea Life Sciences Inc 25 Cytovation AS 25 Foamix Pharmaceuticals Ltd 26 G&E Herbal Biotechnology Co Ltd 26 Laboratories Ojer Pharma SL 27 LEO Pharma A/S 27 Nielsen Biosciences Inc 28 Novan Inc 28 Novartis AG 29 Promius Pharma LLC 29 RXi Pharmaceuticals Corp 30 Tamir Biotechnology Inc 30 Zydus Cadila Healthcare Ltd 31 Warts - Drug Profiles 32 (digoxin + furosemide) - Drug Profile 32 854-A - Drug Profile 34 Albicin - Drug Profile 35 AS-101 - Drug Profile 36 AX-03 - Drug Profile 38 BTA-074 - Drug Profile 40 CyPep-1 - Drug Profile 42 DFD-05 - Drug Profile 43 FIT-039 - Drug Profile 44 furosemide - Drug Profile 45 human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 46 human papillomavirus vaccine - Drug Profile 47 human papillomavirus vaccine - Drug Profile 48 hydrogen peroxide - Drug Profile 49 imiquimod - Drug Profile 52 imiquimod SR - Drug Profile 53 ingenol mebutate - Drug Profile 54 interferon alfa-2b - Drug Profile 56 LFX-453 - Drug Profile 57 omiganan pentahydrochloride - Drug Profile 58 povidone iodine - Drug Profile 60 PP-210 - Drug Profile 61 ranpirnase - Drug Profile 62 RKP-00156 - Drug Profile 65 Samcyprone - Drug Profile 66 SB-206 - Drug Profile 68 SRT-100 - Drug Profile 70 VP-100 - Drug Profile 72 Warts - Dormant Projects 73 Warts - Discontinued Products 74 Warts - Product Development Milestones 75 Featured News & Press Releases 75 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 83 Disclaimer 84
List of Tables
Number of Products under Development for Warts, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Warts - Pipeline by Aclaris Therapeutics Inc, H2 2017 Warts - Pipeline by Agilvax Inc, H2 2017 Warts - Pipeline by Aviragen Therapeutics Inc, H2 2017 Warts - Pipeline by BioMAS Ltd, H2 2017 Warts - Pipeline by Cutanea Life Sciences Inc, H2 2017 Warts - Pipeline by Cytovation AS, H2 2017 Warts - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 Warts - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017 Warts - Pipeline by Laboratories Ojer Pharma SL, H2 2017 Warts - Pipeline by LEO Pharma A/S, H2 2017 Warts - Pipeline by Nielsen Biosciences Inc, H2 2017 Warts - Pipeline by Novan Inc, H2 2017 Warts - Pipeline by Novartis AG, H2 2017 Warts - Pipeline by Promius Pharma LLC, H2 2017 Warts - Pipeline by RXi Pharmaceuticals Corp, H2 2017 Warts - Pipeline by Tamir Biotechnology Inc, H2 2017 Warts - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017 Warts - Dormant Projects, H2 2017 Warts - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.